⌕
Viridian Therapeutics · VRDN · Nasdaq
Tenet 43 · Weak
Compare
$29.80−3.47%At closeTenet 43 · Weak
$29.80−1.07 (−3.47%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Viridian Therapeutics (VRDN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

25 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~121.1%/yr (FY21→FY25), net margin −483.6%. Worth your attention in FY25: Share count (+163.2%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲23359.9%
70.8
FY21→FY25CAGR +121.1%/yr
Net income ($M)▼26.9%
−342.6
FY21→FY25CAGR —
Free cash flow ($M)▼18.9%
−276.9
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+163.2%

32.3mn → 85.1mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.

Capex
$495.0K

steady at 0.7% of revenue (−3.1% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)70.8Revenue0.0COGS−338.9R&D−95.3SG&A−363.4Op income20.8Tax & other−342.6Net income

-484¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~4%FY21FY25

Net margin -483.6% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.749, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
26,309.070,849.0302.0314.01,772.02,963.0▲23359.9%+121.1%
Cost of revenue
1,527.00.00.00.00.00.0——
Gross profit
24,782.0—A—A—A—A—A——
Research & development
308,508.0338,929.0238,254.0159,765.0100,894.056,886.0▲42.3%+56.2%
Selling, general & admin
184,937.095,315.061,083.094,999.035,182.025,805.0▲56.0%+38.6%
Total operating expenses
493,445.0434,244.0299,337.0254,764.0136,076.082,691.0▲45.1%+51.4%
Operating incomefeeds ROC rank
−468,663.0−363,395.0−299,035.0−254,450.0−134,304.0−79,728.0▼21.5%—
Other income, net
14,199.020,794.029,086.016,716.04,430.0315.0——
Pretax income
−454,464.0−342,601.0−269,949.0−237,734.0−129,874.0−79,413.0▼26.9%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−453,584.0−342,601.0−269,949.0−237,734.0−129,874.0−79,413.0▼26.9%—
Per share
Diluted EPSbuyback-sensitive
—B—B—B—B—B—B——
Diluted shares (mn)
113.5985.0868.1945.0032.3211.92▲24.8%+63.5%
Margins
Gross margin91st pct in Healthcare
94.2%—A—A—A—A—A——
Operating margin
−1781.4%−512.9%−99018.2%−81035.0%−7579.2%−2690.8%▲98505.3pp+2177.9pp
Net margin0th pct in Healthcare
−1724.1%−483.6%−89387.1%−75711.5%−7329.2%−2680.2%▲88903.5pp+2196.6pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Viridian Therapeutics' revenue last fiscal year?

Viridian Therapeutics reported revenue of $70.8M in fiscal 2025, up 23359.9% from fiscal 2024.

What was Viridian Therapeutics' net income?

Viridian Therapeutics reported net income of −$342.6M in fiscal 2025, a net margin of −483.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.